These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 1862051)
1. Ventricular arrhythmias. When should they be suppressed? Marcus FI Postgrad Med; 1991 Aug; 90(2):62-4, 67-9. PubMed ID: 1862051 [TBL] [Abstract][Full Text] [Related]
2. Exacerbation of ventricular arrhythmias during the postoperative period after implantation of an automatic defibrillator. Kim SG; Fisher JD; Furman S; Gross J; Zilo P; Roth JA; Ferrick KJ; Brodman R J Am Coll Cardiol; 1991 Nov; 18(5):1200-6. PubMed ID: 1918696 [TBL] [Abstract][Full Text] [Related]
3. Introduction: changing trends in antiarrhythmic therapy: worldwide experience with class III agents. Singh BN; Breithardt G Am J Cardiol; 1997 Oct; 80(8A):1G-3G. PubMed ID: 9354406 [No Abstract] [Full Text] [Related]
5. A benefit-risk assessment of class III antiarrhythmic agents. Brendorp B; Pedersen O; Torp-Pedersen C; Sahebzadah N; Køber L Drug Saf; 2002; 25(12):847-65. PubMed ID: 12241126 [TBL] [Abstract][Full Text] [Related]
7. Risk stratification and clinical outcome of minimally symptomatic and asymptomatic patients with nonsustained ventricular tachycardia and coronary disease: a prospective single-center study. Giorgberidze I; Saksena S; Krol RB; Munsif AN; Kolettis T; Mathew P; Varanasi S; Prakash A; Delfaut P; Lewis CB Am J Cardiol; 1997 Sep; 80(5B):3F-9F. PubMed ID: 9291444 [TBL] [Abstract][Full Text] [Related]
8. Antiarrhythmic agents in older patients. Current state of knowledge. Kim CH; Daubert JP; Akiyama T Drugs Aging; 1994 Jun; 4(6):462-9. PubMed ID: 7521233 [TBL] [Abstract][Full Text] [Related]
9. Can antiarrhythmic drugs survive survival trials? Pratt CM; Waldo AL; Camm AJ Am J Cardiol; 1998 Mar; 81(6A):24D-34D. PubMed ID: 9537220 [TBL] [Abstract][Full Text] [Related]
10. Current clinical perspectives on antiarrhythmic drug therapy. Anderson JL Fed Proc; 1986 Jul; 45(8):2213-9. PubMed ID: 3720963 [TBL] [Abstract][Full Text] [Related]
12. Interactions between implantable cardioverter-defibrillators and class III agents. Movsowitz C; Marchlinski FE Am J Cardiol; 1998 Aug; 82(4A):41I-48I. PubMed ID: 9737653 [TBL] [Abstract][Full Text] [Related]
13. Sudden death in idiopathic dilated cardiomyopathy. Tamburro P; Wilber D Am Heart J; 1992 Oct; 124(4):1035-45. PubMed ID: 1529877 [TBL] [Abstract][Full Text] [Related]
14. [Antiarrhythmic therapy in patients with heart failure]. Faber TS; Zehender M Ther Umsch; 2000 May; 57(5):324-32. PubMed ID: 10859993 [TBL] [Abstract][Full Text] [Related]
15. Treatment of ventricular arrhythmias by United States cardiologists: a survey before the Cardiac Arrhythmia Suppression Trial results were available. Morganroth J; Bigger JT; Anderson JL Am J Cardiol; 1990 Jan; 65(1):40-8. PubMed ID: 1688481 [TBL] [Abstract][Full Text] [Related]
17. [Management of arrhythmias in patients with heart failure]. Le Heuzey JY; Copie X; Piot O; Lavergne T; Henry P; Guize L Arch Mal Coeur Vaiss; 1998 Nov; 91(11):1371-6. PubMed ID: 9864606 [TBL] [Abstract][Full Text] [Related]
18. [Present possibilities of the treatment of malignant ventricular arrhythmia in coronary disease]. Breithardt G; Borggrefe M Dtsch Med Wochenschr; 1985 Dec; 110(51-52):1987-92. PubMed ID: 2416523 [No Abstract] [Full Text] [Related]
19. Ventricular arrhythmias, Part III: Benefits and risks of antiarrhythmic therapy. Grauer K; Gums J J Am Board Fam Pract; 1988; 1(4):255-66. PubMed ID: 3066124 [TBL] [Abstract][Full Text] [Related]
20. Current role of the automatic implantable cardioverter-defibrillator in the treatment of life-threatening ventricular arrhythmias. Kay GN; Plumb VJ; Dailey SM; Epstein AE Am J Med; 1990 Jan; 88(1N):25N-34N. PubMed ID: 2195882 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]